• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Enveric Biosciences

    < Previous 1 2 Next >
    Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces Broad Range of Patent Issuances
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces Patent Granted for Drug Candidate
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Participate in BIO International Convention 2024
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
    From Enveric Biosciences
    Via Business Wire
    Tickers CSE:MBIO ENVB
    Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.